GYRE
Gyre Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$587.99M
P/E Ratio
—
EPS
$-0.08
Beta
5.28
52W High
$11.61
52W Low
$5.97
50-Day MA
$7.26
200-Day MA
$7.66
Dividend Yield
—
Profit Margin
-5.44%
Forward P/E
78.12
PEG Ratio
—
About Gyre Therapeutics Inc.
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company focused on developing groundbreaking therapies for rare and complex diseases through its proprietary platform. With a robust pipeline emphasizing gene therapy and precision medicine, Gyre aims to address critical unmet medical needs while enhancing patient outcomes. The company's commitment to scientific rigor and innovation, coupled with strategic partnerships, positions it for significant growth and impact within the competitive biopharmaceutical sector. As it advances its research and development efforts, Gyre is set to play a transformative role in improving the lives of patients facing challenging health conditions.
Fundamentals
| Revenue (TTM) | $117.05M |
| Gross Profit (TTM) | $111.30M |
| EBITDA | $5.07M |
| Operating Margin | -30.20% |
| Return on Equity | -3.08% |
| Return on Assets | 1.04% |
| Revenue/Share (TTM) | $1.29 |
| Book Value | $1.11 |
| Price-to-Book | 5.82 |
| Price-to-Sales (TTM) | 5.02 |
| EV/Revenue | 4.622 |
| EV/EBITDA | 106.63 |
| Quarterly Earnings Growth (YoY) | 166.20% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $97.03M |
| Float | $21.28M |
| % Insiders | 86.33% |
| % Institutions | 3.75% |
Historical Volatility
HV 10-Day
48.62%
HV 20-Day
69.63%
HV 30-Day
61.08%
HV 60-Day
61.99%
HV Rank
42.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($18.67 target)
3
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026